A physician-supervised GLP-1 weight loss program using FDA-approved branded medications. Monthly labs, real medical oversight, no shortcuts that get clinics shut down.
GLP-1 medications — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — are the most effective weight loss medications ever brought to market. Used properly, with medical supervision, they produce 15–22% average body weight reduction at 52 weeks in clinical trials. That's transformative.
Used badly — through telehealth-only "prescription mills" that skip lab work, monthly follow-ups, and proper medical oversight — they can cause significant side effects, drug interactions, and rebound weight gain when stopped abruptly. The medication is the easy part. The medicine around it is what determines outcomes.
Our program is built around what GLP-1 weight loss actually requires: a medical evaluation, baseline labs, monthly physician check-ins, dose titration based on response and side effects, and a long-term plan for either maintenance or transition off the medication. We use FDA-approved branded medications. Compounded alternatives are available in narrow patient-specific circumstances per federal guidance — we'll explain when and why at consultation.
Branded medications with full FDA approval for weight management. Our default choice.
Five phases over the first six months. We don't shortcut any of them.
Full medical history, current medications, baseline labs (metabolic panel, lipids, A1c, thyroid). We screen for contraindications and weight-related comorbidities to confirm medical eligibility.
Begin on the lowest titration dose (0.25mg semaglutide / 2.5mg tirzepatide). We teach injection technique, set expectations for side effects, and provide rescue protocols for nausea management.
Dose increases every 4 weeks based on tolerance and response. Most patients reach maintenance dose by week 16. Some stay at lower doses if response is strong or side effects significant.
Physician check-ins monthly: weight tracking, side effects, dose adjustments, lab work at month 3 and month 6. We adjust based on actual response, not a fixed protocol.
After meaningful weight loss, we discuss long-term plan: continued maintenance dose, taper to lower dose, or transition off medication with lifestyle support. There's no one right answer.
Branded FDA-approved medications are our default. Compounded options exist only in narrow patient-specific circumstances per federal guidance — and they cost more in medical oversight, not less.
Compounded semaglutide or tirzepatide from a licensed 503A compounding pharmacy. Available only via patient-specific prescription when clinically justified.
Note: Compounded GLP-1 medications are not FDA-approved as finished drugs. Their use requires patient-specific clinical justification under FDA 503A pharmacy rules. We will discuss whether you qualify at consultation. If FDA-approved branded medication is available and clinically appropriate, that is our default recommendation.
Wegovy®, Zepbound®, or Saxenda®. Full FDA approval. Standard of care for medical weight management.
Note: Branded medication cost varies by insurance coverage. Cash price ranges $1,000–$1,300/month; many commercial insurance plans cover with prior authorization. We help patients navigate coverage and patient-assistance programs.
The medical weight loss market is in a regulatory transition. Here's what's changed, and what we do about it.
The FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — meaning bulk-compounded versions of these medications would no longer be permitted at outsourcing facilities. Comment period closes June 29, 2026. The likely outcome: bulk-compounded GLP-1 will be substantially restricted, with continued narrow availability via patient-specific 503A pathways.
This matters because many "$199/month" telehealth companies have been operating on bulk-compounded supply. As regulations tighten, those operations face progressively narrower legal ground.
Our approach: FDA-approved branded medications as default, narrow patient-specific 503A compounding only when clinically justified, full medical oversight always. We'd rather be expensive and compliant than cheap and at-risk.
Wegovy and Zepbound are. "Compounded semaglutide" and "compounded tirzepatide" are not FDA-approved finished drugs — they're compounded preparations. Both have legitimate uses, but they're not the same thing legally or clinically.
"Physician supervision" should mean monthly visits, lab work, and the ability to adjust treatment based on your response. Not a one-time intake form and a recurring shipment.
Baseline labs (metabolic panel, lipids, A1c, thyroid) are standard of care before starting GLP-1. Ongoing labs at month 3 and month 6 catch developing side effects early. Programs that skip labs are skipping medicine.
Rebound weight gain after stopping GLP-1 is well-documented when no transition plan exists. A real program discusses maintenance, taper, or transition off medication before you start, not after.
Medical eligibility is established at consultation with labs and medical history review. General guidelines below.
"Lost 38 pounds on Zepbound in six months. The monthly check-ins and lab work made the difference — I didn't feel like I was just buying a prescription online. When I had nausea issues in month two, my physician adjusted the dose. That's medicine. That's what was missing from the cheaper options I'd tried before."
Common questions about medical weight loss. Bring anything else to consultation.
Four short questions. Someone from our team follows up within one business day to schedule your medical evaluation and discuss program fit.